Ratings by Brookline Capital Markets
| Date | Analyst | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|---|
| 6/10/2026 | Tyler Bussian | CervoMed | CRVO | Maintain | Buy (N/A) |
15.00 (N/A) |
|
Details | |
| 6/8/2026 | Leah Rush Cann | Kymera Therapeutics | KYMR | Maintain | Buy (N/A) |
97.00 (91.00) |
|
Details | |
 |
|||||||||
|
|||||||||
|
|||||||||
|
|||||||||
|
|||||||||
|
|||||||||
|
|||||||||
|
|||||||||
| 296 more... | |||||||||
